Gabather AB (publ)

GABA · Nasdaq Stockholm · Healthcare

0.03SEK −1.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −24.6%

Performance

1 month

−18.9%

1 year

−24.6%

3 years, per year

−76.1%

5 years, per year

−65.6%

Largest fall, 3 years

−99.5%

Below the peak now

−100.0%

Volatility, 1 year

133.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

10.4

Dividend yield

0.0%

Return on equity

−341.5%

Net margin

–

Market value

2 m USD

Quality, value and trend

Where Gabather stands against every Nordic stock today. 100 is best.

Quality63

Profitability and a sound balance sheet over time. Better than 63% of Nordic stocks.

Value1

The price measured against earnings, assets and cash flow. Better than 1% of Nordic stocks.

Trend12

The price development over the past year. Better than 12% of Nordic stocks.

Combined8

Quality, value and trend together. Better than 8% of Nordic stocks.

About Gabather

Gabather AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 2 employees.

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis